Although mechanistic interpretations are difficult, the metabolite changes at the early stages following injection for the FN075-treated mice match metabolic profiles obtained in newly diagnosed Parkinson’s disease patients in terms of both identity of altered metabolites and direction of change.27 In contrast, analysis of serum from Snca KO mice demonstrated no significant difference in metabolic profile (P=0.136) when comparing samples from 3-month-old FN075-injected mice with vehicle-injected mice. This evidence concerns the gene SNCA and Parkinson disease.